Human cell lines for biopharmaceutical manufacturing: history,status, and future perspectives

Biotherapeutic proteins represent a mainstay of treatment for a multitude of conditions, for example, autoimmune disorders, hematologic disorders, hormonal dysregulation, cancers, infectious diseases and genetic disorders. The technologies behind their production have changed substantially since biotherapeutic proteins were first approved in the 1980s. Although most biotherapeutic proteins developed to date have been produced using the mammalian Chinese hamster ovary and murine myeloma (NS0, Sp2/0) cell lines, there has been a recent shift toward the use of human cell lines. One of the most important advantages of using human cell lines for protein production is the greater likelihood that the resulting recombinant protein will bear post-translational modifications (PTMs) that are consistent with those seen on endogenous human proteins. Although other mammalian cell lines can produce PTMs similar to human cells, they also produce non-human PTMs, such as galactose-α1,3-galactose and N-glycolylneuraminic acid, which are potentially immunogenic. In addition, human cell lines are grown easily in a serum-free suspension culture, reproduce rapidly and have efficient protein production. A possible disadvantage of using human cell lines is the potential for human-specific viral contamination, although this risk can be mitigated with multiple viral inactivation or clearance steps. In addition, while human cell lines are currently widely used for biopharmaceutical research, vaccine production and production of some licensed protein therapeutics, there is a relative paucity of clinical experience with human cell lines because they have only recently begun to be used for the manufacture of proteins (compared with other types of cell lines). With additional research investment, human cell lines may be further optimized for routine commercial production of a broader range of biotherapeutic proteins.     

Preparation and polymerization properties of monomeric ADP-actin

An improved method for the preparation of Mg-ADP-actin and Ca-ADP-actin which minimizes denaturation of the protein has been developed. Using ADP-actin prepared by this method, we have measured the polymerization characteristics of Mg-ADP-actin and Ca-ADP-actin. In contrast to the significant difference in Mg-ATP-actin and Ca-ATP-actin polymerization characteristics that we reported previously (J. Muscle Res. Cell Motility 7 (1986) 215-224), we show here that values for the critical concentration, the relative rate constant of elongation (mk+) and the relative rate constant of depolymerization (mk-) for Mg-ADP-actin are similar to those for Ca-ADP-actin. The value of mk+ for Mg-ATP-actin is about 8-fold higher than that for Mg-ADP-actin and the value of mk- for Mg-ADP-actin is 3-4-fold higher than that for Mg-ATP-actin. These factors may help explain the observation that the spontaneous nucleation rates of both types of ADP-actin are low in contrast to the rapid nucleation of Mg-ATP-actin.     

Lymphocyte plasma membranes II. Cytochemical localization of 5′-nucleotidase in rat lymphocytes

Cytochemical studies of thymic and splenic lymphocytes from rats showed that 5′-nucleotidase was restricted to the plasma membranes. Isolated plasma membranes contained the highest specific activity of 5′-nucleotidase of any cellular fractions. The results indicate that this enzyme can be used as a plasma membrane marker for lymphocytes.     

东北小鲵中枢神经系统形态学与组织学初步研究

本文应用脊椎动物神经标本制作法和HE染色法,对东北小鲵中枢神经系统的外部形态和组织学结构进行了初步研究,描述了东北小鲵神经系统形态和组织学结构的特点,并与无尾两栖类和爬行类相对比,探讨了有尾两栖类的进化地位。结果表明:与无尾两栖类(如蛙)相比,东北小鲵中枢神经系统中,大脑半球较小,结构较为原始,小脑结构简单,是两栖类中较为原始的类群。此外,东北小鲵开始具有了臂神经丛和骶神经丛,但没有爬行类的发达,可作为两栖类向爬行类进化的证据之一。     

植物丝氨酸/精氨酸丰富(SR)蛋白的结构和功能及其在植物发育中的作用

丝氨酸／精氨酸丰富（SR）蛋白家族是真核生物中的一类剪接因子,在前体mRNA的组成性和选择性剪接中起作用。本文就近十几年来SR蛋白结构和功能及其在植物发育中的作用的研究进展作以介绍。